Shingrix Provides Exceptional Protection Against Shingles in Elderly Adults
Shingrix (recombinant zoster vaccine, RZV) is strongly recommended for all adults aged 50 years and older, delivering outstanding 91-97% efficacy against herpes zoster (shingles) and 89% efficacy against postherpetic neuralgia (PHN), with sustained protection exceeding 73% at 10 years. 1
Key Benefits by Age Group
Ages 50-69 Years
- 97.2% efficacy against herpes zoster across all age groups in this range 1
- Protection remains consistent regardless of specific age within this bracket
- Real-world effectiveness of 76% with 2 doses 2
Ages 70+ Years
- 89.8% efficacy in preventing herpes zoster 1
- 91.3% efficacy in pooled analysis of adults ≥70 years 1
- 88.8% efficacy against postherpetic neuralgia specifically 1
- Effectiveness remains 75% even in those aged ≥80 years 3
Duration of Protection
Protection is remarkably durable:
- Efficacy maintained >83% for up to 8 years 1
- Decreases to 73% at 10 years 1
- Real-world data shows 79% effectiveness in year 1,75% in year 2, and 73% in years 3-4 after completing the 2-dose series 2
This represents a dramatic improvement over the older live vaccine (Zostavax), which showed waning from 51% to only 21% efficacy over 7-11 years 1.
Critical Dosing Considerations
Two doses are essential for optimal protection:
- 2-dose effectiveness: 76% 2
- 1-dose effectiveness: only 57-64% 2, 3
- After 1 dose alone, protection drops from 70% in year 1 to just 45% in year 2 2
- Second dose can be given 2-6 months after the first (minimum 4 weeks if needed) 4, 5
- Delayed second doses beyond 6 months do not impair effectiveness 3
Prevention of Complications
Shingrix provides superior protection against the most debilitating complication:
- 76-85% effectiveness against postherpetic neuralgia (PHN) in real-world use 3, 6
- PHN is the chronic, severe nerve pain that can persist for months to years after shingles
- This benefit directly improves quality of life by preventing long-term disability
Special Populations
Immunocompromised Adults
- 64% effectiveness in immunocompromised individuals 6
- 65% effectiveness in those receiving corticosteroids 2
- 66% effectiveness in autoimmune diseases 6
- FDA-approved for adults ≥18 years who are immunocompromised 5
Common Comorbidities
- 67% effectiveness in diabetes 6
- 63% effectiveness in liver disease 6
- Effectiveness maintained across all studied chronic conditions
Safety Profile
The vaccine is well-tolerated with no increase in serious adverse events:
- No difference in serious adverse events or deaths compared to placebo 1
- Common transient reactions include:
- These reactions are temporary and resolve within days
Clinical Bottom Line
Shingrix represents a transformative advance in preventing shingles and its complications in elderly adults. The vaccine delivers >90% efficacy that is sustained for at least a decade, far superior to the older live vaccine. The two-dose series is critical—single-dose protection wanes rapidly and should be avoided. While injection site reactions are common, they are transient and vastly outweighed by the prevention of a painful, potentially debilitating disease.
Common Pitfall: Failing to complete the 2-dose series. Emphasize to patients that the second dose is not optional—it's essential for durable protection. Even if the second dose is delayed beyond 6 months, it should still be given rather than restarting the series 3.
Contraindication: History of severe allergic reaction to any vaccine component or previous Shingrix dose 5.